Bristol Signs Two Cancer Immunotherapy Partners With Eye On Combos
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol will pay $50 million upfront to use CytomX’s Probody platform for up to four cancer immunotherapy targets. The company also partnered with InCyte to study its PD-1 inhibitor nivolumab with Incyte’s oral indoleamine dioxygenase-1 inhibitor.